Skip to main content

Advertisement

Contact Igor Puzanov

From: Updated results and correlative FDG-PET analysis of a phase IB study of vemurafenib and cobimetinib (MEK inhibitor [GDC-0973]), in advanced BRAFV600- mutated melanoma (BRIM7)

Contact corresponding author